Destiny Pharma is working in collaboration with SporeGen Limited, a UK biotechnology company working exclusively on Bacillus and its applications, to co-develop SporeGen’s SPOR-COV™ product as a novel, preventive treatment for COVID-19.
SPOR-COV™ prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment
The SPOR COV™ product consists of a proprietary formulation of Bacillus bacteria that will be administered nasally as a spray. SPOR-COV™ has already been shown by SporeGen to provide complete (100%) protection in preclinical models of influenza.
SPOR-COV™ is different to vaccines in that it utilises the innate immune system with the aim of developing COVID-19 protection within a few days after dosing. As an “easy to use” first line of defence, it has the potential to reduce COVID-19 infection rates and transmission significantly. The final SPOR-COV™ product is planned to be straightforward to produce at both high volumes and at low cost. Additional attributes are that it can be stockpiled almost indefinitely without the need for cold chain refrigeration as it is a very stable product. It could be made available globally as a cost-effective measure in the fight against COVID-19 as well as new COVID strains and other respiratory viral infections.